Status:
UNKNOWN
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Leukemia
Transplantation, Hematopoietic Stem Cell
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients re...
Detailed Description
Patients will recieve caspofungin with either voriconazole or amphotericin B as combination therapy for fungal infection
Eligibility Criteria
Inclusion
- adult patient undergoing allogeneic hematopoietic stem cell transplantation
- age 18-55 years
- with inform consent
- no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage
- HLA mismatched related (3\~5/6) or unrelated donors (at least 8/10)
- proven or probable IFI
Exclusion
- age less than 18 years or over 56 years
- HLA mismatched related donor
- liver function/renal function damage (over 2 X upper normal range)
- with mental disease
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT01501708
Start Date
December 1 2011
End Date
December 1 2017
Last Update
May 10 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, China, 200025